Clinical trials: Oral Cavity Cancer
Head and Neck Cancer
Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005088
- Testing
- cisplatin, radiation therapy
- Where
- 258 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Oral Mucositis, Pediatric Cancer
Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment
The main objective of this study is to assess the impact of non-invasive photodynamic therapy by Curcumin and photo-bio-modulation low level (LL) laser treatment in managing mucositis induced by chemotherapy in pediatric…
- Trial name
- NCT06044142
- Testing
- Curcumin, Laser
- Where
- Saudi Arabia
- Volunteers
- 90 people
- Sponsor
- Riyadh Elm University
Acute Lymphobkastic Leukemia, Medication Adherence
The AYA Oncology Self-care Movement
This trial will test the impact of a social media intervention for improving oral chemotherapy adherence among adolescents and young adults (AYAs) with acute lymphoblastic leukemia.
- Trial name
- #AYAOSM (NCT07724652)
- Testing
- Educational Website, #AYAOSM
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Advanced Solid Tumor, Metastatic Solid Tumor
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
- Trial name
- NCT06577987
- Testing
- CID-078 Monotherapy
- Where
- 10 sites in United States
- Volunteers
- 220 people
- Sponsor
- Circle Pharma
Carcinoma, Non-Small-Cell Lung
Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study
The study is designed for subjects whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer.
- Trial name
- NCT00256815
- Testing
- chemotherapy, Radiation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Clinical Oncology Research Associates
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells.
- Trial name
- NCT00003717
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- St. Barnabas Medical Center
Potentially Malignant Lesions, Oral Lichen Planus
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.
- Conditions
- Potentially Malignant Lesions, Oral Lichen Planus, Leukoplakia, Oral
- Trial name
- NCT05730855
- Testing
- Real-time Polymerase Chain Reaction technique
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Refractory Solid Tumor, Hepatocellular Carcinoma
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent…
- Conditions
- Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor, Pediatric Cancer
- Trial name
- NCT05468359
- Testing
- Atezolizumab, Sorafenib, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- St. Jude Children's Research Hospital
Parotid Tumor
The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome
The aim of the study was to explore whether human acellular dermal matrix (ADM) implantation could prevent infraauricular depressed deformities and Frey's syndrome following total parotidectomy.
- Trial name
- NCT01414790
- Testing
- ADM
- Where
- China
- Volunteers
- 70 people
- Sponsor
- West China Hospital
Prostate Cancer, Urinary Incontinence
Prospective RCT on Post Prostatectomy Urine Leak
Objectives: Primary: Comparison of proportion of patient achieving continence between the four arms at 6 months. Secondary: Comparison of time to achieve continence between the four arms.
- Trial name
- NCT02367404
- Testing
- Duloxetine, Pelvic Floor Muscle Training
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Institut Mutualiste Montsouris
Urinary Catheters, Rectal Cancer
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer.
- Conditions
- Urinary Catheters, Rectal Cancer, Urinary Retention
- Trial name
- NCT07346586
- Testing
- Tamsulosin group, 24-Hour Removal Group, 48-Hour Removal Group
- Where
- 2 sites in China
- Volunteers
- 1,545 people
- Sponsor
- The First Hospital of Jilin University
Esophageal Cancer, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002951
- Testing
- fluorouracil, hydroxyurea, surgical procedure
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Head and Neck Cancer, Oral Complications
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00008398
- Testing
- sargramostim, quality-of-life assessment, radiation therapy
- Where
- 236 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with salvage surgery and radiation.
- Trial name
- UAB0718 (NCT00570232)
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Melanoma
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
Matrix metalloproteinases (MMPs) are a class of membrane bound enzymes that are involved in the degradation of the extracellular matrix. MMP-2 and MMP-9 have been associated with the progression of cancer.
- Conditions
- Lymphoma, Melanoma, Neoplasm Metastasis, Renal Cell Carcinoma
- Trial name
- NCT00001683
- Testing
- COL-3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Leukemia
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00080873
- Testing
- Traumeel S
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 195 people
- Sponsor
- Children's Oncology Group
Locally Advanced Cervical Cancer
A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer
The cervix cancer is the second malignant neoplasia more common between women. The combined treatment involving chemotherapy and radiotherapy was defined as the standard.
- Trial name
- PHOENIX I (NCT01217177)
- Testing
- everolimus
- Where
- 2 sites in Brazil
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals